January 15, 2021Open Access

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

Key Points

Key points are not available for this paper at this time.

Abstract

Combination treatment with eprenetapopt and azacitidine is well-tolerated yielding high rates of clinical response and molecular remissions in patients with TP53-mutant MDS and oligoblastic AML.

Bookmark

View Full Paper

Cite This Study

Sallman et al. (Fri,) studied this question.

synapsesocial.com/papers/69dffb672833447a7e255d2d https://doi.org/https://doi.org/10.1200/jco.20.02341

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes2020 · 131 citations
2Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia2006 · 1,586 citations
3Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia2019 · 98 citations
4Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes2020 · 632 citations
5Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)2020 · 47 citations

Bookmark

View Full Paper